Cheerful mid-stage depression drug data send Axsome stock flying
On the same day Sage rolled out $SAGE tremendous oral drug data in postpartum depression, Axsome Therapeutics has announced that its lead experimental CNS drug induced statistically significant improvements in patients with major depressive disorder (MDD) in a mid-stage study, prompting the company’s stock $AXSM to skyrocket more than 150% in pre-market trading on Monday.
In general, trials testing depression drugs are notoriously tricky and prone to failure, in major part due to high rates of the placebo effect.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.